Pavel Skok
Affiliations: | Faculty of Medicine | Univerza v Mariboru (Slovenia) |
Area:
Medicine and Surgery, Biochemistry, Microbiology BiologyGoogle:
"Pavel Skok"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Jezernik G, Glavač D, Skok P, et al. (2024) Discovery of Novel Biomarkers with Extended Non-Coding RNA Interactor Networks from Genetic and Protein Biomarkers. International Journal of Molecular Sciences. 25 |
| Gorenjak M, Gole B, Goričan L, et al. (2024) Single-Cell Transcriptomic and Targeted Genomic Profiling Adjusted for Inflammation and Therapy Bias Reveal and as Novel Hub Genes for Anti-Tumor Necrosis Factor Alpha Therapy Response in Crohn's Disease. Pharmaceutics. 16 |
| Gorenjak M, Jezernik G, Krušič M, et al. (2022) Identification of Novel Loci Involved in Adalimumab Response in Crohn's Disease Patients Using Integration of Genome Profiling and Isoform-Level Immune-Cell Deconvoluted Transcriptome Profiling of Colon Tissue. Pharmaceutics. 14 |
| Gorenjak M, Zupin M, Jezernik G, et al. (2021) Omics data integration identifies ELOVL7 and MMD gene regions as novel loci for adalimumab response in patients with Crohn's disease. Scientific Reports. 11: 5449 |
| Gorenjak M, Repnik K, Jezernik G, et al. (2019) Genetic prediction profile for adalimumab response in Slovenian Crohn's disease patients. Zeitschrift Fur Gastroenterologie. 57: 1218-1225 |
| Repnik K, Koder S, Skok P, et al. (2016) Transferrin Level Before Treatment and Genetic Polymorphism in HFE Gene as Predictive Markers for Response to Adalimumab in Crohn's Disease Patients. Biochemical Genetics |
| Zupančič K, Skok K, Repnik K, et al. (2016) Multi-locus genetic risk score predicts risk for Crohn's disease in Slovenian population. World Journal of Gastroenterology. 22: 3777-84 |
| Koder S, Repnik K, Ferkolj I, et al. (2015) Genetic polymorphism in ATG16L1 gene influences the response to adalimumab in Crohn's disease patients. Pharmacogenomics. 16: 191-204 |
| Štabuc B, Tepeš B, Skok P, et al. (2015) Guidelines for the prevention and management of gastrointestinal adverse effects in patients receiving nonsteroidal anti-inflammatory and antiaggregant therapy Zdravniski Vestnik. 84: 3-15 |
| Gorenjak M, Gradišnik L, Trapečar M, et al. (2014) Improvement of lipid profile by probiotic/protective cultures: study in a non-carcinogenic small intestinal cell model. The New Microbiologica. 37: 51-64 |